Growth Hormone:
More Lean Mass, but How Much More Muscle?

A 2019 meta-analysis of 11 randomized trials in healthy young adults found a pooled 2.72 kg increase in lean body mass versus placebo. At the same time, total body water increased 1.10 kg and extracellular water increased 1.78 kg. Fat mass fell 0.67 kg. The pooled effects on measured muscle protein synthesis and strength were essentially null.^[1]

The confidence intervals make the body-composition findings statistically clear. They do not solve the interpretation problem. “Lean” is a subtraction category: everything that is not fat or bone mineral is generally counted inside it. A DXA result therefore cannot tell you how much of a change came from contractile protein, cellular water, extracellular fluid, glycogen-associated water, connective tissue or organ mass.

For hypertrophy, the most persuasive pattern would be concordance: larger muscle on imaging or biopsy, larger fibers, increased myofibrillar protein accretion and greater force after adequate training. GH trials in healthy adults frequently produce the first broad body-composition signal without the later functional signals.^[2][5][13]

This is why method choice matters. Body weight is least specific. Bioimpedance is highly sensitive to fluid assumptions. DXA is useful for whole-body composition but still labels a hydration-sensitive soft-tissue compartment. CT and MRI can measure an anatomical muscle cross-section or volume more directly, yet even a larger muscle can contain more water and connective tissue without proportional gains in force. Biopsy and tracer studies answer still narrower questions.

GH is especially prone to this endpoint gap because it affects sodium and water retention as well as connective tissue. The official somatropin label identifies fluid retention, peripheral edema, arthralgia, myalgia, paresthesia and carpal-tunnel syndrome as dose-dependent adult effects. A “fuller” look and a higher lean-mass reading can therefore be pharmacologically real without being a one-for-one measure of new muscle fibers.^[11][12]

Resistance training did the muscular work; GH enlarged a different lean compartment

In a classic trial in young men, resistance exercise increased muscle size, strength and muscle protein synthesis. Adding GH produced a larger rise in fat-free mass but did not further increase those muscular adaptations. The investigators concluded that the extra fat-free mass probably reflected lean tissue other than skeletal muscle.^[5]

Later systematic reviews reached the same broad conclusion. In healthy young adults, GH consistently changes body composition; effects on strength, endurance and power are limited or absent across short placebo-controlled trials. The literature is not large, durations are usually measured in weeks rather than years, and athletic outcomes are heterogeneous—but the mismatch between the scan and the strength test is remarkably persistent.^[1][2][13]

The notable exception was sprint capacity—not maximal strength

A blinded randomized trial enrolled 96 recreational athletes aged 18–40 years for eight weeks. GH increased lean mass by about 2.7 kg, and secondary analyses attributed roughly 70% of that change to extracellular fluid. It did not clearly improve strength, aerobic capacity or jump height. It did improve anaerobic sprint capacity by 3.8% compared with placebo.^[3][13]

That result deserves neither dismissal nor inflation. A short sprint benefit could matter in a narrow performance setting. It does not establish larger contractile muscle, and one trial is not a universal athlete effect. The pooled literature still describes modest body-composition changes with limited evidence for the outcomes that dominate strength and endurance sports.^[2]

The cleanest mechanistic clue comes from a two-week randomized crossover experiment in 10 healthy young men. Recombinant GH increased collagen-related gene expression and collagen protein synthesis in tendon and muscle. It did not increase myofibrillar protein synthesis—the contractile fraction people usually mean when they talk about hypertrophy.^[4]

This makes the mechanism more interesting, not less. Tendon and extracellular matrix are part of adaptation. Connective-tissue remodeling could theoretically affect force transmission or tissue tolerance. But a collagen tracer result in uninjured volunteers does not prove faster return from injury, stronger tendons or fewer tears. Clinical healing needs injury-specific trials with imaging, function, recurrence and adverse-event outcomes.

The same distinction applies to “muscle collagen.” A tissue sample can become more anabolic in its connective compartment without adding the myofibrillar machinery that generates force. Calling both responses muscle growth erases the biology the experiment was designed to reveal.

Adult GH deficiency is a clinical disorder associated with pituitary or hypothalamic disease, surgery, radiation, trauma or defined childhood-onset conditions. Diagnosis generally requires appropriate stimulation testing unless the clinical context already establishes a high-probability structural or genetic cause. A low-normal random GH or IGF-1 result in a healthy lifter is not the same diagnosis.^[9][10][11]

In a meta-analysis of 15 blinded placebo-controlled trials involving 306 adults with GH deficiency, three to 12 months of replacement increased measured muscle volume by 7.1% and aerobic capacity by 8.9%; VO₂max rose by 0.17 L/min. The pooled strength change was 3.2% and was not statistically significant (P=.15).^[9]

The distinction is familiar in endocrinology. Thyroid hormone can transform outcomes in true hypothyroidism without being a general performance enhancer in euthyroid people. Likewise, replacement can restore physiology that disease removed; it does not tell us what supraphysiologic exposure adds when the GH–IGF-1 axis is intact.

Longer observational follow-up in treated deficiency may show greater functional improvement than short randomized trials, but it also introduces time, training, selection and dose-adjustment effects. For the narrow hypertrophy question, the best causal evidence remains the blinded placebo-controlled evidence—and even in deficiency, short-term strength trails muscle-volume and aerobic-capacity changes.^[9][12]

Androgen-receptor signaling has direct, dose-responsive effects on skeletal-muscle size and strength in controlled testosterone studies. GH works through a different network: direct GH-receptor actions, IGF-1 signaling, fluid balance, lipolysis and tissue-specific protein synthesis. Both can raise a lean-mass number, but the composition and function behind that number need not match.

A 26-week randomized trial in 131 healthy adults aged 65–88 illustrates the problem. In men, lean mass increased 1.4 kg with testosterone, 3.1 kg with GH and 4.3 kg with the combination, versus 0.1 kg with placebo. Yet strength was not broadly improved; the GH-plus-testosterone group showed only a marginal increase in one aggregate strength measure, while male VO₂max improved in the combination group. The factorial design is useful, but this was an older population and the combination cannot reveal a bodybuilding effect of either drug in isolation.^[7]

So it is reasonable to say that GH and testosterone can be additive on a body-composition endpoint in older men. It is not reasonable to convert that study into a healthy-young-athlete cycle, to assume the added mass was all muscle, or to treat combination results as proof of synergy for hypertrophy. The testosterone evidence guide reviews the human dose–response data separately.

Somatropin reduces insulin sensitivity, and official labeling warns that impaired glucose tolerance or type 2 diabetes can be unmasked during treatment. It also warns about intracranial hypertension, fluid retention, hypoadrenalism, hypothyroidism and other population-specific risks. Active malignancy, acute critical illness in specified settings and several other conditions are contraindications.^[11]

Trials in healthy older adults make those risks visible. Across the 2007 systematic review, GH recipients experienced more edema, arthralgia, carpal-tunnel syndrome and gynecomastia. In the Blackman trial, 18 GH-treated men developed diabetes or glucose intolerance compared with seven men who did not receive GH. Carpal-tunnel symptoms occurred in 32% of men receiving GH plus testosterone versus none on placebo; arthralgia affected 41% of men receiving GH alone versus none on placebo.^[6][7]

Those percentages come from small trial arms and should not be treated as universal incidence estimates. They do show why adverse effects are part of efficacy interpretation rather than a footnote. If a 2–3 kg lean-mass gain is substantially fluid, then fluid-related symptoms are not unrelated noise—they are evidence about what produced the number.

Growth hormone is a potent physiological signal. It changes substrate use, connective-tissue turnover, water balance and the IGF-1 axis. In true adult GH deficiency, supervised replacement can improve body composition, muscle volume, aerobic capacity and quality of life. In healthy adults, it reliably raises lean mass and lowers fat mass modestly.^{[1][6][9][10][12]}

But the hypertrophy claim outruns the evidence when “lean mass” is translated directly into “new muscle.” Healthy-adult trials repeatedly show more fat-free mass without proportional myofibrillar synthesis or strength. The most revealing mechanistic study found a collagen response while contractile protein synthesis stayed flat. The most notable athletic trial found a small sprint benefit, not a broad strength advantage.^[2][3][4][5]

The honest answer is not that GH is inert. It is that GH appears better at changing the composition of lean tissue than at proving the functional muscle growth most lifters actually want. Future trials would be far more useful if they combined DXA with MRI muscle volume, water-compartment measurement, fiber or myofibrillar endpoints, standardized resistance training and prespecified strength tests. Until then, the scan is a clue—not the conclusion.